KR880007726A - 안정하게 형질감염된 포유동물 세포에서 사람 에리트로포이에틴 유전자를 고농도 형질발현시키는 방법 - Google Patents

안정하게 형질감염된 포유동물 세포에서 사람 에리트로포이에틴 유전자를 고농도 형질발현시키는 방법

Info

Publication number: KR880007726A
Authority: KR; South Korea
Prior art keywords: stably transfected; human erythropoietin; high concentration; mammalian cells; expressing human
Prior art date: 1986-06-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

KR1019870006561A

Other languages

English (en)

Other versions

KR970009935B1 (ko

Inventor

에스 포우엘 제리

Original Assignee

보드 오브 리젠츠 오브 디 유니버시티 오브 워싱턴

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-27

Filing date

1987-06-27

Publication date

1988-08-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25374134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880007726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-06-27 Application filed by 보드 오브 리젠츠 오브 디 유니버시티 오브 워싱턴 filed Critical 보드 오브 리젠츠 오브 디 유니버시티 오브 워싱턴

1988-08-29 Publication of KR880007726A publication Critical patent/KR880007726A/ko

1997-06-19 Application granted granted Critical

1997-06-19 Publication of KR970009935B1 publication Critical patent/KR970009935B1/ko

2007-06-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10341—Use of virus, viral particle or viral elements as a vector
- C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

KR1019870006561A 1986-06-27 1987-06-27 안정하게 형질감염된 포유동물 세포에서 사람 에리트로포이에틴 유전자를 고농도 형질발현시키는 방법 Expired - Lifetime KR970009935B1 (ko)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87942386A	1986-06-27	1986-06-27
US879,423		1986-06-27

Publications (2)

Publication Number	Publication Date
KR880007726A true KR880007726A (ko)	1988-08-29
KR970009935B1 KR970009935B1 (ko)	1997-06-19

Family

ID=25374134

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019870006561A Expired - Lifetime KR970009935B1 (ko)	1986-06-27	1987-06-27	안정하게 형질감염된 포유동물 세포에서 사람 에리트로포이에틴 유전자를 고농도 형질발현시키는 방법

Country Status (17)

Country	Link
US (3)	US5688679A (ko)
EP (1)	EP0255231B1 (ko)
JP (1)	JPS63126488A (ko)
KR (1)	KR970009935B1 (ko)
CN (2)	CN1044133C (ko)
AT (1)	ATE76431T1 (ko)
AU (1)	AU611088B2 (ko)
BR (1)	BR8703269A (ko)
CA (1)	CA1341361C (ko)
DE (1)	DE3779206D1 (ko)
DK (1)	DK173067B1 (ko)
ES (1)	ES2037083T3 (ko)
FI (1)	FI95393C (ko)
GR (1)	GR3004707T3 (ko)
NO (1)	NO303398B1 (ko)
PT (1)	PT85193B (ko)
WO (1)	WO1988000241A1 (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK173067B1 (da) *	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US6048729A (en)	1987-05-01	2000-04-11	Transkaryotic Therapies, Inc.	In vivo protein production and delivery system for gene therapy
US4974929A (en) *	1987-09-22	1990-12-04	Baxter International, Inc.	Fiber optical probe connector for physiologic measurement devices
US6063630A (en) *	1991-11-05	2000-05-16	Transkaryotic Therapies, Inc.	Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
PT101031B (pt) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) *	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US6054288A (en) *	1991-11-05	2000-04-25	Transkaryotic Therapies, Inc.	In vivo protein production and delivery system for gene therapy
US6692737B1 (en)	1991-11-05	2004-02-17	Transkaryotic Therapies, Inc.	In vivo protein production and delivery system for gene therapy
US5968502A (en) *	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US6670178B1 (en)	1992-07-10	2003-12-30	Transkaryotic Therapies, Inc.	In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en)	1992-07-10	2003-03-11	Transkaryotic Therapies, Inc.	In vivo production and delivery of insulinotropin for gene therapy
US6153407A (en) *	1992-07-28	2000-11-28	Beth Israel Deaconess Medical Center	Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
AU1095595A (en) *	1993-11-10	1995-05-29	Amgen, Inc.	Gene therapy vector for the treatment of low or defective red blood cell production
US5919758A (en) *	1994-03-22	1999-07-06	Beth Israel Deaconess Medical Center	Modified polypeptides with altered biological activity
US5888774A (en) *	1994-12-19	1999-03-30	Cangene Corporation	Recombinant DNA molecules and expression vectors for erythropoietin
US5952226A (en) *	1996-11-05	1999-09-14	Modex Therapeutiques	Hypoxia responsive EPO producing cells
US6187564B1 (en)	1997-07-10	2001-02-13	Beth Israel Deaconess Medical Center	DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6177545B1 (en) *	1997-09-02	2001-01-23	Insight Strategy & Marketing Ltd.	Heparanase specific molecular probes and their use in research and medical applications
US20020088019A1 (en) *	1997-09-02	2002-07-04	Oron Yacoby-Zeevi	Methods of and pharmaceutical compositions for improving implantation of embryos
US20040213789A1 (en) *	1997-09-02	2004-10-28	Oron Yacoby-Zeevi	Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20030161823A1 (en) *	1998-08-31	2003-08-28	Neta Ilan	Therapeutic and cosmetic uses of heparanases
US6699672B1 (en)	1997-09-02	2004-03-02	Insight Biopharmaceuticals Ltd.	Heparanase specific molecular probes and their use research and medical applications
US6897066B1 (en) *	1997-09-26	2005-05-24	Athersys, Inc.	Compositions and methods for non-targeted activation of endogenous genes
ES2221717T3 (es)	1997-12-08	2005-01-01	Emd Lexigen Research Center Corp.	Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US6777205B1 (en)	1998-11-06	2004-08-17	Sterrenbeld Biotechnologie North America, Inc.	Host cells expressing recombinant human erythropoietin
BR9917606A (pt)	1998-11-06	2002-12-31	Bio Sidus S A	Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
BR9905868A (pt)	1998-11-06	2001-01-23	Bio Sidus S A	Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
EP1157118A4 (en) *	1999-03-01	2002-07-17	Insight Strategy & Marketing	POLYNUCLEOTID ENCODING A POLYPEPTIDE WITH HEPARANASE ACTIVITY AND ITS EXPRESSION IN GENETICALLY MODIFIED CELLS
EP1181036B1 (en) *	1999-04-09	2008-07-23	Ortho-Mcneil Pharmaceutical, Inc.	Pharmaceutical compositions of erythropoietin
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en)	1999-08-09	2003-09-09	Emd Lexigen Research Center Corp.	Multiple cytokine protein complexes
JP2003514552A (ja)	1999-11-12	2003-04-22	メルクパテントゲゼルシャフトミットベシュレンクテルハフトング	改善された性質を有するエリトロポエチンの形態
PT1252192E (pt) *	2000-02-11	2007-01-31	Merck Patent Gmbh	Melhoramento da semivida de circulação de proteínas de fusão à base de anticorpos
US7259146B2 (en)	2000-05-26	2007-08-21	Ortho-Mcneil Pharmaceutical, Inc.	Neuroprotective peptides
PL358582A1 (en) *	2000-06-29	2004-08-09	Merck Patent Gmbh	Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7078376B1 (en) *	2000-08-11	2006-07-18	Baxter Healthcare S.A.	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE60138404D1 (de)	2000-09-25	2009-05-28	Baylor College Medicine	Verbessertes system zur regulation der transgenexpression
CA2437333A1 (en) *	2001-02-02	2002-08-22	Ortho-Mcneil Pharmaceutical, Inc.	Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
HUP0303428A2 (hu)	2001-03-07	2004-01-28	Merck Patent Gmbh.	Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
ATE502053T1 (de)	2001-05-03	2011-04-15	Merck Patent Gmbh	Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
US6671189B2 (en) *	2001-11-09	2003-12-30	Minebea Co., Ltd.	Power converter having primary and secondary side switches
CA2468499A1 (en) *	2001-11-28	2003-06-05	Ortho-Mcneil Pharmaceutical, Inc.	Erythropoietin dosing regimen for treating anemia
DK1454138T3 (da)	2001-12-04	2012-02-13	Merck Patent Gmbh	Immunocytokiner med moduleret selektivitet
AU2003218045A1 (en) *	2002-03-11	2003-09-29	Ortho Mcneil Pharmaceutical, Inc	Methods for shp1 mediated neuroprotection
DE10234192B4 (de) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
DE60333121D1 (de)	2002-12-17	2010-08-05	Merck Patent Gmbh	Pers 14.18, der gd2 bindet und seine fusion mit il-2
EP2338333B1 (en)	2003-04-09	2017-09-06	ratiopharm GmbH	Glycopegylation methods and proteins/peptides produced by the methods
WO2004108065A2 (en) *	2003-06-09	2004-12-16	Insight Biopharmaceuticals Ltd.	Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
US7141544B2 (en) *	2003-10-10	2006-11-28	Baxter International, Inc.	Stabilization of pharmaceutical protein formulations with small peptides
CN1902222A (zh)	2003-12-31	2007-01-24	默克专利有限公司	具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
US7423139B2 (en) *	2004-01-20	2008-09-09	Insight Biopharmaceuticals Ltd.	High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050238628A1 (en) *	2004-04-08	2005-10-27	Blau Carl A	Methods for treating cancer
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
US7772182B2 (en) *	2004-08-05	2010-08-10	Alza Corporation	Stable suspension formulations of erythropoietin receptor agonists
US7597884B2 (en)	2004-08-09	2009-10-06	Alios Biopharma, Inc.	Hyperglycosylated polypeptide variants and methods of use
CN101062407A (zh)	2006-04-29	2007-10-31	中国科学院上海生命科学研究院	促红细胞生成素在预防或治疗视网膜损伤中的用途
JP2010510794A (ja)	2006-11-28	2010-04-08	ハナルファーマシューティカルカンパニーリミテッド	修飾型エリスロポエチンポリペプチド及びこの治療用用途
US20090143255A1 (en) *	2007-11-30	2009-06-04	Funkhouser Gary P	Methods and Compositions for Improving Well Bore Stability in Subterranean Formations
CA2712606A1 (en)	2008-02-08	2009-08-13	Ambrx, Inc.	Modified leptin polypeptides and their uses
US20120172299A1 (en)	2008-09-23	2012-07-05	F. Hoffmann-La Roche Ag	Purification of erythropoietin
DK2342223T3 (en)	2008-09-26	2017-07-24	Ambrx Inc	Modified animal erythropoietin polypeptides and their uses
ES2629630T3 (es)	2008-12-04	2017-08-11	Curna, Inc.	Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
WO2013120500A1 (en) *	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
EP2970420A4 (en)	2013-03-15	2016-08-17	Apotex Inc	STABILITY OF THE ENHANCED LIQUID FORMULATION OF ERYTHROPOIETIN ALPHA VIA A PURIFICATION TREATMENT
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP6245299B2 (ja) *	2016-04-27	2017-12-13	バクスアルタゲーエムベーハー	組換え安定細胞クローン、その産生およびその使用
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6045849B2 (ja) *	1980-08-25	1985-10-12	林原健	ヒトエリトロポエチンの製造方法
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) *	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
IT1185503B (it) *	1984-01-11	1987-11-12	Univ New York	Cloni di odna di eritropietina umana
IL77081A (en) *	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
AU580145B2 (en) *	1985-02-13	1989-01-05	Scios Nova Inc.	Human metallothionein-ii promoter in mammalian expression system
US4751084A (en) *	1986-02-26	1988-06-14	Monsanto Company	Tissue plasminogen activator from normal human colon cells
DE3789678T2 (de) *	1986-02-27	1994-08-11	Snow Brand Milk Prod Co Ltd	Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
DK173067B1 (da)	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition

1987
- 1987-06-17 DK DK198703093A patent/DK173067B1/da not_active IP Right Cessation
- 1987-06-22 CA CA000616544A patent/CA1341361C/en not_active Expired - Fee Related
- 1987-06-23 WO PCT/US1987/001459 patent/WO1988000241A1/en active IP Right Grant
- 1987-06-25 ES ES198787305672T patent/ES2037083T3/es not_active Expired - Lifetime
- 1987-06-25 DE DE8787305672T patent/DE3779206D1/de not_active Expired - Lifetime
- 1987-06-25 AT AT87305672T patent/ATE76431T1/de not_active IP Right Cessation
- 1987-06-25 EP EP87305672A patent/EP0255231B1/en not_active Expired - Lifetime
- 1987-06-26 CN CN87104424A patent/CN1044133C/zh not_active Expired - Lifetime
- 1987-06-26 PT PT85193A patent/PT85193B/pt not_active IP Right Cessation
- 1987-06-26 BR BR8703269A patent/BR8703269A/pt not_active Application Discontinuation
- 1987-06-26 AU AU74757/87A patent/AU611088B2/en not_active Expired
- 1987-06-26 CN CNA2006101006871A patent/CN101041819A/zh active Pending
- 1987-06-27 KR KR1019870006561A patent/KR970009935B1/ko not_active Expired - Lifetime
- 1987-06-27 JP JP62160799A patent/JPS63126488A/ja active Pending
1988
- 1988-02-26 FI FI880899A patent/FI95393C/fi not_active IP Right Cessation
- 1988-02-26 NO NO880863A patent/NO303398B1/no not_active IP Right Cessation
1992
- 1992-05-26 GR GR920401043T patent/GR3004707T3/el unknown
1993
- 1993-10-06 US US08/132,489 patent/US5688679A/en not_active Expired - Lifetime
2001
- 2001-10-10 US US09/975,063 patent/US6867020B2/en not_active Expired - Fee Related
- 2001-11-05 US US10/011,858 patent/US6682910B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6867020B2 (en)	2005-03-15
AU611088B2 (en)	1991-06-06
FI95393B (fi)	1995-10-13
GR3004707T3 (ko)	1993-04-28
ES2037083T3 (es)	1993-06-16
NO880863D0 (no)	1988-02-26
DK309387A (da)	1987-12-28
US5688679A (en)	1997-11-18
FI880899L (fi)	1988-02-26
PT85193B (pt)	1990-08-31
US20020137145A1 (en)	2002-09-26
FI880899A0 (fi)	1988-02-26
ATE76431T1 (de)	1992-06-15
DK309387D0 (da)	1987-06-17
US6682910B2 (en)	2004-01-27
CN87104424A (zh)	1988-04-27
PT85193A (en)	1987-07-01
DK173067B1 (da)	1999-12-13
FI95393C (fi)	1996-01-25
US20020045255A1 (en)	2002-04-18
CN101041819A (zh)	2007-09-26
EP0255231B1 (en)	1992-05-20
KR970009935B1 (ko)	1997-06-19
CN1044133C (zh)	1999-07-14
EP0255231A1 (en)	1988-02-03
JPS63126488A (ja)	1988-05-30
NO880863L (no)	1988-04-26
WO1988000241A1 (en)	1988-01-14
NO303398B1 (no)	1998-07-06
DE3779206D1 (de)	1992-06-25
AU7475787A (en)	1988-01-07
CA1341361C (en)	2002-05-21
BR8703269A (pt)	1988-03-15

Publication	Publication Date	Title
KR880007726A (ko)	1988-08-29	안정하게 형질감염된 포유동물 세포에서 사람 에리트로포이에틴 유전자를 고농도 형질발현시키는 방법
DK463586D0 (da)	1986-09-29	Fsh
NO964445D0 (no)	1996-10-18	DNA-sekvens, vektor, vertscelle og fremgangsmåte for transfeksjon av hematopoeseceller med eksogen DNA
DE3888642D1 (de)	1994-04-28	Rollflasche zur Züchtung von Zellengewebekulturen.
ATE177472T1 (de)	1999-03-15	Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
EP0226448A3 (en)	1989-01-11	Solubilisation of protein aggregates
ATE109829T1 (de)	1994-08-15	Interleukin-7.
DE3784846D1 (de)	1993-04-22	Zellkulturapparat.
GB2196636B (en)	1990-09-19	Production of proteins by cell culture
DE69432856D1 (de)	2003-07-31	Zufuhr von genprodukten mittels mesangium-zellen
FI945877A0 (fi)	1994-12-14	Menetelmä proteiini C:n tuottamiseksi
NO175872C (no)	1994-12-21	Plasmidvektor, fremgangsmåte for fremstilling av peptider og myelomcelle
DE3485981D1 (de)	1992-12-17	Biosynthetische 2,5-diketoglukonsaeure-reduktase, verfahren, rekombinante zellen und expressionsvektoren zu deren herstellung und ihre verwendung zur herstellung von 2-keto-l-gulonsaeure.
ES8405842A1 (es)	1984-07-01	Procedimiento de producir razas estables de celulas de mamiferos
ATE129287T1 (de)	1995-11-15	Bakterielles kollagenase-gen.
FI873153L (fi)	1988-01-20	Menetelmä ihmisen antitrombiini III:n (ATIII:n) valmistamiseksi nisäkässoluviljelmässä sekä tähän soveltuvia vektoreita ja nisäkäsisäntäsoluja
GR3003950T3 (ko)	1993-03-16
DE3679067D1 (de)	1991-06-06	Stabilisierte wasserstoffperoxydzusammensetzung, deren herstellungsverfahren und verwendung.
ATE51555T1 (de)	1990-04-15	Verstaerkte platte, deren herstellungsverfahren und apparat zur ausfuehrung dieses verfahrens.

Legal Events

Date	Code	Title	Description
1987-06-27	PA0109	Patent application	Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19870627
1988-08-29	PG1501	Laying open of application
1992-06-27	A201	Request for examination
1992-06-27	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 19920627 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19870627 Comment text: Patent Application
1996-02-28	E902	Notification of reason for refusal
1996-02-28	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 19960228 Patent event code: PE09021S01D
1996-12-17	E902	Notification of reason for refusal
1996-12-17	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 19961217 Patent event code: PE09021S01D
1997-05-24	G160	Decision to publish patent application
1997-06-19	PG1605	Publication of application before grant of patent	Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19970524
1997-08-18	O035	Opposition [patent]: request for opposition
1997-08-18	PO0301	Opposition	Comment text: Request for Opposition Patent event code: PO03011R01D Patent event date: 19970818
1998-07-08	E601	Decision to refuse application
1998-07-08	O063	Decision on refusal after opposition [patent]: decision to refuse application
1998-07-08	PO0601	Decision on refusal after opposition	Comment text: Decision to Refuse Application Patent event date: 19980708 Patent event code: PO06011S01D
1998-08-19	J201	Request for trial against refusal decision
1998-08-19	PJ0201	Trial against decision of rejection	Patent event date: 19980819 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 19980708 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 19990929 Appeal identifier: 1998101002550 Request date: 19980819
1999-10-05	J301	Trial decision	Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19980819 Effective date: 19990929 Free format text: TRIAL NUMBER: 1998101002550; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19980819 Effective date: 19990929
1999-10-05	PJ1301	Trial decision	Patent event code: PJ13011S01D Patent event date: 19991005 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 19980819 Decision date: 19990929 Appeal identifier: 1998101002550
1999-11-08	J2X1	Appeal (before the patent court)	Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 1999201008653; APPEAL AGAINST DECISION TO DECLINE REFUSAL
1999-11-08	PJ2001	Appeal	Patent event date: 19991005 Comment text: Trial Decision on Objection to Decision on Refusal Patent event code: PJ20011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20010622 Appeal identifier: 1999201008653 Request date: 19991108
2001-06-26	J302	Written judgement (patent court)	Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19991108 Effective date: 20010622 Free format text: TRIAL NUMBER: 1999201008653; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19991108 Effective date: 20010622
2001-06-26	PJ1302	Judgment (patent court)	Patent event date: 20010626 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 19991108 Decision date: 20010622 Appeal identifier: 1999201008653 Appeal kind category: Appeal against decision to decline refusal
2001-07-09	J2X2	Appeal (before the supreme court)	Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2001301002238; APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL
2001-07-09	PJ2002	Appeal before the supreme court	Comment text: Trial Decision on Objection to Decision on Refusal Patent event date: 19991005 Patent event code: PJ20021S01I Request date: 20010709 Appeal identifier: 2001301002238 Appeal kind category: Appeal against decision to decline refusal Decision date: 20021108
2002-11-16	J303	Written judgement (supreme court)	Free format text: JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010709 Effective date: 20021108 Free format text: TRIAL NUMBER: 2001301002238; JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010709 Effective date: 20021108
2002-11-16	PJ1303	Judgment (supreme court)	Comment text: Written Judgment (Supreme Court) Patent event date: 20021116 Patent event code: PJ13031S01D Decision date: 20021108 Appeal kind category: Appeal against decision to decline refusal Request date: 20010709 Appeal identifier: 2001301002238